- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04353284
Camostat Mesylate in COVID-19 Outpatients
The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is designed as a double-blind randomized controlled clinical trial to test the hypothesis that camostat mesylate, a serine protease inhibitor shown to inhibit SARS-COV-2 replication in vitro, inhibits SARS-COV-2 replication in early stage, laboratory-confirmed, COVID-19 ambulatory patients.
Camostat mesylate, a serine protease inhibitor used primarily for treating postoperative reflux esophagitis and for acute exacerbations of chronic pancreatitis. This drug, with more than 15 years clinical experience in Japan with a very safe clinical track record, will be studied as a repurposed drug based on published in vitro virus inhibition data and in vivo protective effects in a mouse model of SARS.
The primary objective of this study is to determine whether camostat mesylate reduces SARS-COV-2 viral load in early COVID-19 disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be enrolled within 3 days of being notified of their first positive COVID-19 test result.
- Evidence of a recent active COVID-19 infection, as evidenced by the positive test results being associated with at least one COVID-19-compatible symptom such as fever, upper respiratory symptoms, cough, chills, loss of taste/smell, etc.(see COVID-19-PRO symptom score sheet), or a recent high-risk exposure to COVID-19
- Provision of informed consent.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Diagnosed with COVID-19 within past 3 days and not exhibiting manifestations requiring hospitalization such as extreme shortness of breath or severe prostration. Nurses at the study site will assess such severe conditions requiring hospitalization, which would preclude enrollment.
- Ability to take oral medication and be willing to adhere to the camostat mesylate regimen.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of the camostat mesylate administration.
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.
- Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration.
- English and Spanish speaking subjects as well as patients speaking any language for which we can find appropriate translators will be enrolled. A short form with interpretation will be used for anyone speaking a language for which a translated informed consent form is not currently available in accordance with local site IRB policies, including developing certified translations as necessary.
Exclusion Criteria:
- Presence of COVID-19 disease manifestations that would require referral for consideration of hospitalization.
- A previous positive COVID-19 test reported more than 7 days before, which would indicate likelihood of non-culturable, nonreplicating virus.
- A positive COVID-19 test without a known recent exposure that would indicate an active infection, hence an unknown chance of non-culturable, non-replicating virus being present (i.e., asymptomatic COVID-19 infection of unknown duration).
- Pregnancy or lactation.
- Known allergic reactions to components of camostat mesylate.
- With regard to inclusion or exclusion of women of child-bearing potential, women who report that they know they are pregnant are excluded. All women of child-bearing potential who test positive for pregnancy by urine test at first visit are excluded. A day 14 followup blood pregnancy test will be done on appropriate enrolled women (i.e. those who had a negative urine pregnancy test on day 0 for further safety assessment ).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Camostat mesylate
Camostat mesylate 200mg taken 7 days.
|
Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
Other Names:
|
Placebo Comparator: Placebo
Placebo taken for 7 days.
|
Placebo taken orally, 4 times daily, for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in SARS-COV-2 Viral Load
Time Frame: 5 days (day 0 to day 4)
|
To determine whether camostat mesylate reduces SARS-COV-2 viral load (N Gene) in early COVID-19 disease, change from day 0 to day 4 in respiratory (oropharyngeal swab RT-PCR) log10 viral load will be assessed.
|
5 days (day 0 to day 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in SARS-COV-2 Viral Load
Time Frame: 3 days (day 0 to day 2)
|
To determine whether camostat mesylate reduces SARS-COV-2 viral load (N Gene) in early COVID-19 disease, change from day 0 to day 2 in respiratory (oropharyngeal swab RT-PCR) log10 viral load will be assessed.
|
3 days (day 0 to day 2)
|
Change in SARS-COV-2 Viral Load
Time Frame: 7 days (day 0 to day 6)
|
To determine whether camostat mesylate reduces SARS-COV-2 viral load (N Gene) in early COVID-19 disease, change from day 0 to day 6 in respiratory (oropharyngeal swab RT-PCR) log10 viral load will be assessed.
|
7 days (day 0 to day 6)
|
Number of Participants With Change in Positive COVID-19 Status
Time Frame: 7 days
|
Change in risk for a positive COVID-19 test at day 6 after enrollment (day 0) will be assessed by analyzing the proportion of positive cases in each study arm.
|
7 days
|
Number of Participants With Change in Positive COVID-19 Status
Time Frame: 14 days
|
Change in risk for a positive COVID-19 test at day 13 after enrollment (day 0) will be assessed by analyzing the proportion of positive cases in each study arm.
|
14 days
|
Change in Positive COVID-19 Status
Time Frame: 28 days
|
Number of Participants With Change in Positive COVID-19 Status
|
28 days
|
Change in COVID-19 Symptom Severity
Time Frame: Day 0 to Day 6
|
Change of COVID-19 symptom severity from day 0 to day 6 will be assessed with the COVID-19 daily self score tool.
Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily.
Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much.
These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms.
Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more.
These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency.
The last question (39) asks patients for their highest temperature in Fahrenheit.
|
Day 0 to Day 6
|
Change in COVID-19 Symptom Severity
Time Frame: Day 0 to Day 13
|
Change of COVID-19 symptom severity from day 0 to day 14 will be assessed with the COVID-19 daily self score tool.
Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily.
Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much.
These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms.
Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more.
These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency.
The last question (39) asks patients for their highest temperature in Fahrenheit.
|
Day 0 to Day 13
|
Change in COVID-19 Symptom Frequency
Time Frame: Day 0 to Day 6
|
Change of COVID-19 symptom frequency score from day 0 to day 6 will be assessed with the COVID-19 daily self score tool.
Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily.
Items 34-38 measure the frequency of specific daily symptoms and are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more.
These items are summed to score the frequency of symptoms- where the highest score (20) indicates the greatest burden of symptom frequency, the lowest possible score (0) indicates no frequency of symptoms.
|
Day 0 to Day 6
|
Change in COVID-19 Symptom Frequency
Time Frame: Day 0 to Day 13
|
Change of COVID-19 symptom frequency score from day 0 to day 6 will be assessed with the COVID-19 daily self score tool.
Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily.
Items 34-38 measure the frequency of specific daily symptoms and are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more.
These items are summed to score the frequency of symptoms- where the highest score (20) indicates the greatest burden of symptom frequency, the lowest possible score (0) indicates no frequency of symptoms.
|
Day 0 to Day 13
|
Change in Body Temperature
Time Frame: 7 days (Day 0 to Day 6)
|
Change of COVID-19 symptom score from baseline to day 6 will be assessed with the COVID-19 daily self score tool.
Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily.
Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much.
These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms.
Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more.
These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency.
The last question (39) asks patients for their highest temperature in Fahrenheit.
|
7 days (Day 0 to Day 6)
|
Change in Body Temperature
Time Frame: 28 days
|
Change of COVID-19 symptom score from baseline to 28 days will be assessed with the COVID-19 daily self score tool.
Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily.
Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much.
These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms.
Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more.
These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency.
The last question (39) asks patients for their highest temperature in Fahrenheit.
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Geoffrey Chupp, M.D., Director, Yale Center for Asthma and Airways Disease (YCAAD)
- Principal Investigator: Joseph Vinetz, M.D., Professor, Section of Infectious Diseases: Department of Internal Medicine
Publications and helpful links
General Publications
- Kosinsky Y, Peskov K, Stanski DR, Wetmore D, Vinetz J. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. Microbiol Spectr. 2022 Apr 27;10(2):e0216721. doi: 10.1128/spectrum.02167-21. Epub 2022 Apr 12.
- Chupp G, Spichler-Moffarah A, Sogaard OS, Esserman D, Dziura J, Danzig L, Chaurasia R, Patra KP, Salovey A, Nunez A, May J, Astorino L, Patel A, Halene S, Wang J, Hui P, Patel P, Lu J, Li F, Gan G, Parziale S, Katsovich L, Desir GV, Vinetz JM. A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste. medRxiv. 2022 Jan 31:2022.01.28.22270035. doi: 10.1101/2022.01.28.22270035. Preprint.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Serine Proteinase Inhibitors
- Anticoagulants
- Trypsin Inhibitors
- Camostat
- Gabexate
Other Study ID Numbers
- 2000027971
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Camostat Mesilate
-
Heinrich-Heine University, DuesseldorfThe Federal Ministry of Health, Germany (Bundesministerium für Gesundheit...CompletedCorona Virus Infection | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 PCR Test PositiveGermany
-
Cancer Research UKLatus TherapeuticsTerminatedCOVID-19 InfectionUnited Kingdom
-
Sagent Pharmaceuticals Inc.Completed
-
Alan BryceUnknownSevere Acute Respiratory SyndromeUnited States
-
Stanford UniversityCompleted
-
University of AarhusRecruitingCorona Virus InfectionDenmark, Sweden
-
Heinrich-Heine University, DuesseldorfUniversitätsklinikum Hamburg-Eppendorf; University Hospital Frankfurt; St. Georg... and other collaboratorsWithdrawn
-
Instituto Nacional de Ciencias Medicas y Nutricion...TerminatedHypertension | Obesity | Diabetes | Covid19Mexico
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedCoronavirus Infection | Covid19 | SARS-CoV InfectionUnited States
-
Opiant Pharmaceuticals IncCompleted